Related Experiment Videos
Heart transplantation for radiation-associated end-stage heart failure
N Handa1, C G McGregor, R C Daly
1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Summary
Heart transplantation offers excellent short-term results for patients with end-stage heart failure caused by mediastinal radiation therapy. This approach shows promise for managing radiation-induced heart disease, with no observed recurrence or secondary malignancies.
Area of Science:
- Cardiology
- Oncology
- Radiotherapy
Background:
- Mediastinal radiation therapy for cancer can lead to late-onset heart disease.
- Radiation-induced heart disease is a recognized complication requiring advanced treatment strategies.
Observation:
- Four patients with end-stage heart failure due to mediastinal radiation therapy underwent heart transplantation.
- These patients had previously received radiation for malignant neoplasms.
Findings:
- All four patients survived a mean of 48 months post-transplantation.
- Excellent short-term and intermediate-term outcomes were observed.
- No instances of secondary malignancy or recurrence of the primary cancer were reported.
Implications:
- Heart transplantation is a viable and encouraging option for managing end-stage radiation-induced heart disease.
- The procedure demonstrates favorable safety and efficacy in this patient cohort.
- Further research into long-term outcomes is warranted.